Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | PDE4A | P27815 | 4/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907924 | 0.81 | SMN1; SMN2 (0.58) | MAPK1PDE4AADORA2BCYP1A2BLM | |
| SCHEMBL14907910 | 0.81 | SMN1; SMN2 (0.58) | MAPK1PDE4AADORA2APDE4BPDE4C | |
| SCHEMBL18990403 | 0.77 | PDE4A (0.57) | MAPK1PDE4AADORA2APDE4BPDE4C | |
| SCHEMBL14907967 | 0.77 | PDE4A (0.55) | MAPK1PDE4AADORA2APDE4BPDE4C | |
| SCHEMBL15869887 | 0.76 | SMN1; SMN2 (0.53) | MAPK1PDE4AADORA2BCYP1A2BLM | |
| SCHEMBL19006914 | 0.76 | MAPK1 (0.53) | MAPK1PDE4AADORA2APDE4BPDE4C | |
| SCHEMBL15869886 | 0.76 | SMN1; SMN2 (0.53) | MAPK1PDE4AADORA2APDE4BPDE4C | |
| SCHEMBL21360607 | 0.75 | TRPA1 (0.47) | MAPK1PDE4DCYP1A2CYP3A4BLM | |
| SCHEMBL18989514 | 0.74 | MAPK1 (0.66) | MAPK1ADORA2BCYP1A2CYP3A4BLM | |
| Caffeine SCHEMBL28012764 | 0.74 | ADORA2B (0.57) | MAPK1PDE4AADORA2APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753333-B1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED INC (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2753333-B1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9169255-B2 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEO TECH INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169255-B2 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEO TECH INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169255-B2 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | PROTEO TECH INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2014-07-10 | — | — | US | disclosed |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2014-07-10 | — | — | US | disclosed |
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED, INC. | 2014-07-10 | — | — | US | disclosed |
| WO-2013062762-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194447-A1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | SNCA, PARK7, APP | MAPK1 1343/4885PDE4A 1703/4885ADORA2A 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.